NR1I3
MOLECULAR TARGETnuclear receptor subfamily 1 group I member 3
NR1I3 (nuclear receptor subfamily 1 group I member 3) is targeted by 11 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting NR1I3
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Clotrimazole | 2.20 | 8 |
| 2 | Ethinyl Estradiol | 1.39 | 3 |
| 3 | Meclizine | 1.10 | 2 |
| 4 | Phenobarbital | 1.10 | 2 |
| 5 | cbd | 0.69 | 1 |
| 6 | Simvastatin | 0.69 | 1 |
| 7 | Bosentan | 0.69 | 1 |
| 8 | cannabidiol | 0.69 | 1 |
| 9 | Oxycodone | 0.69 | 1 |
| 10 | Rimonabant | 0.69 | 1 |
| 11 | Troglitazone | 0.69 | 1 |
About NR1I3 as a Drug Target
NR1I3 (nuclear receptor subfamily 1 group I member 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 11 compounds with documented NR1I3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
NR1I3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.